Emerging Treatment Options for Myelodysplastic Syndromes

Emerging Treatment Options for Myelodysplastic Syndromes

James K. Mangan, MD, PhD, describes the management of the myelodysplastic syndromes, a diverse group of clonal hematopoietic stem or progenitor cell disorders, as represented by clinical trials presented at ASH 2015 and currrent enrolling clinical trials at Penn Medicine. Dr. Mangan provides algorithms for the treatment of primary, intermediate and high-risk MDS and their respective prognoses as determined by somatic mutations, as well as current and evolving therapies at each level of severity.


Published

December 6, 2016

Created by

Penn Physician VideoLink